Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
nutritional and metabolic diseases | D009750 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ATORVALIQ | CMP Pharma | N-213260 RX | 2023-02-01 | 1 products, RLD, RS |
LIPITOR | Upjohn | N-020702 RX | 1996-12-17 | 4 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CADUET | Pharmacia & Upjohn | N-021540 RX | 2004-01-30 | 11 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
amlodipine and atorvastatin | ANDA | 2025-05-23 |
amlodipine besylate and atorvastatin calcium | ANDA | 2021-02-16 |
atorvastatin calcium | ANDA | 2025-05-28 |
caduet | New Drug Application | 2025-03-03 |
lipitor | New Drug Application | 2024-04-15 |
lypqozet | ANDA | 2024-01-24 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercholesterolemia | D006937 | — | — | — | — | 30 | 9 | 1 | 40 |
Coronary disease | D003327 | — | — | — | — | 7 | 4 | 1 | 12 |
Coronary artery disease | D003324 | — | I25.1 | — | — | 6 | 5 | 1 | 12 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 6 | 4 | 1 | 11 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 6 | 2 | 1 | 9 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 2 | 4 | — | 6 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | 1 | — | 3 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 2 | 1 | — | 3 |
Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | — | 3 | — | — | 3 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 3 | — | — | 3 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 2 | — | — | 2 |
Homozygous familial hypercholesterolemia | D000090542 | — | — | — | — | 1 | — | — | 1 |
Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
Carotid artery diseases | D002340 | EFO_0003781 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 1 | — | — | — | — | 1 |
Hyperlipoproteinemias | D006951 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Atorvastatin |
INN | atorvastatin |
Description | Atorvastatin is a dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases. It has a role as an environmental contaminant and a xenobiotic. It is an aromatic amide, a member of monofluorobenzenes, a statin (synthetic), a dihydroxy monocarboxylic acid and a member of pyrroles. It is functionally related to a heptanoic acid. It is a conjugate acid of an atorvastatin(1-). |
Classification | Small molecule |
Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O |
PDB | — |
CAS-ID | 134523-00-5 |
RxCUI | — |
ChEMBL ID | CHEMBL1487 |
ChEBI ID | 39548 |
PubChem CID | 60823 |
DrugBank | DB01076 |
UNII ID | A0JWA85V8F (ChemIDplus, GSRS) |